Pharmaceutical

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to...

HealthLynked Launches New Enterprise Healthcare Solutions Website and Upgraded Provider Directory to Expand Strategic Value Across the Healthcare Market

NAPLES, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneer in healthcare technology...

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold...

Bio Usawa Biotechnology (Bio Usawa) Partners with DEK Vaccines Ltd (DEK) to Expand Access to Life-Saving Biopharmaceuticals Across Ghana and West Africa

Strategic Distribution Agreement Aims to Address Africa's Growing Non-Communicable Disease Burden with Affordable, World-Class TherapiesKIGALI, Rwanda and SAN FRANCISCO and...

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo,...

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...

error: Content is protected !!